Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crushed Ticagrelor vs Eptifibatide + Clopidogrel in Troponin-Negative ACS
NCT02925923Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) and unstable angina (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Change in High-on Treatment Platelet Reactivity at 24 hours. Started Nov 2016; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)unstable angina
Beyond the preview
Go deeper on NCT02925923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02925923.